ArticleClinical cancer research : an official journal of the American Association for Cancer Research2021

Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors.

Naoko Takebe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.